0
     

Report Added
Report already added
Monoclonal Antibodies for Oncology: Global Markets

Monoclonal Antibodies for Oncology: Global Markets

Report Scope:

The current report provides detailed exposure of global monoclonal antibodies for the oncology market. This report highlights the current and future market potential of monoclonal antibodies for oncology treatment and includes a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections to 2027 and market share for key market players. The report details the market share of monoclonal antibodies for oncology based on type and application. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the impact of the COVID-19 pandemic on this market.

Report Includes:

- 25 data tables and 24 additional tables
- A brief general outlook of the global monoclonal antibodies for oncology market
- Analyses of the global market trends, with market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential of monoclonal antibodies for oncology treatment, and areas of focus to forecast this market into various segments and sub-segments
- Evaluation of the actual market size for monoclonal antibodies in oncology treatment, forecasted growth trends, and corresponding market share analysis by type of antibody, application area, and region
- Technology assessment of the key drivers, restraints and opportunities that will shape the market over the next five years (2022 to 2027)
- In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
- Review of the patent landscape and new developments in the market for monoclonal antibodies for oncology and associated clinical trials
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
- Company profiles of major players, including AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc.
Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Monoclonal Antibodies
History of Monoclonal Antibodies
Advantages and Disadvantages of Monoclonal Antibodies
Monoclonal Antibodies in Oncology
Types of Monoclonal Antibodies
Chapter 4 Market Dynamics
Market Drivers
Increasing Incidence of Cancer
New Product Launches
Rising Healthcare Expenditures and Government Funding
Licensing and Collaboration Agreements
Market Barriers
Price Controls
Regulatory Approval Pressures
Entry of Biosimilars
Opportunities
Impact of COVID-19
Chapter 5 Market Breakdown by Type
Types of Monoclonal Antibodies for Oncology
Market Overview
Market Revenue
Global Market for Monoclonal Antibodies in Oncology by Type
Humanized Monoclonal Antibodies
Human Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Chapter 6 Market Breakdown by Application
Overview
Lung Cancer
Market Size and Forecast
Breast Cancer
Market Size and Forecast
Colorectal Cancer
Market Size and Forecast
Blood Cancer
Market Size and Forecast
Other Cancers
Market Size and Forecast
Chapter 7 Market Breakdown by Region
Introduction
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Chapter 8 Regulatory Aspects
New Approvals of Monoclonal Antibodies for Oncology
Recalls, Withdrawals, and Safety Alerts
Chapter 9 Patent Review/ New Developments
New Developments
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Chapter 10 Competitive Landscape
Mergers, Acquisitions, and Collaborations
Company Market Shares
Chapter 11 Company Profiles
AMGEN INC.
ASTRAZENECA PHARMACEUTICALS
BRISTOL-MYERS SQUIBB
ELI LILLY
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO. INC.
MERCK KGAA
PFIZER INC.
SANOFI S.A.
SEAGEN

List of Tables
Summary Table A : Global Market for Monoclonal Antibodies in Oncology, Through 2027
Summary Table B : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027
Table 1 : Evolution of Monoclonal Antibodies
Table 2 : Advantages and Disadvantages of Monoclonal Antibodies
Table 3 : Monoclonal Antibodies Approved for Oncology
Table 4 : Murine Monoclonal Antibodies
Table 5 : Chimeric Monoclonal Antibodies
Table 6 : Humanized Monoclonal Antibodies
Table 7 : Human Monoclonal Antibodies
Table 8 : Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020
Table 9 : Funding, by Research Areas, 2020
Table 10 : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027
Table 11 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 12 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 13 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 14 : Global Market for Monoclonal Antibodies in Oncology, by Application, Through 2027
Table 15 : Global Market Market for Monoclonal Antibodies for Lung Cancer, by Region, Through 2027
Table 16 : Global Market Market for Monoclonal Antibodies for Breast Cancer, by Region, Through 2027
Table 17 : Global Market Market for Monoclonal Antibodies for Colorectal Cancer, by Region, Through 2027
Table 18 : Global Market Market for Monoclonal Antibodies for Blood Cancer, by Region, Through 2027
Table 19 : Numbers for All Cancers (Except Non-Melanoma Skin Cancer), 2020
Table 20 : Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, Through 2027
Table 21 : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 22 : North American Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 23 : Cancer Incidence and Mortality, Age Standardized Rate, per 100,000, by Cancer Type, EU Countries, 2020
Table 24 : European Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 25 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 26 : Newly Approved Monoclonal Antibodies for Oncology, 2019-April 2022
Table 27 : Recalls, Withdrawals, and Safety Alerts, 2019-April 2022
Table 28 : Monoclonal Antibodies for Oncology in Phase I Clinical Trials
Table 29 : Monoclonal Antibodies for Oncology in Phase II Clinical Trials
Table 30 : Monoclonal Antibodies for Oncology in Phase III Clinical Trials
Table 31 : M&A: Pharmaceutical Companies
Table 32 : Sales of Blockbuster Monoclonal Antibodies for Oncology, 2021
Table 33 : Amgen: Financial Performance, 2019-2021
Table 34 : AstraZeneca: Financial Performance, 2019-2021
Table 35 : AstraZeneca: Business Segment
Table 36 : Bristol-Myers Squibb: Financial Performance, 2019-2021
Table 37 : Eli Lilly: Business Segments
Table 38 : Eli Lilly: Financial Performance, 2019-2021
Table 39 : F. Hoffmann-La Roche: Business Segments
Table 40 : F. Hoffmann-La Roche: Financial Performance, 2019-2021
Table 41 : Johnson & Johnson: Business Segments
Table 42 : Johnson & Johnson: Financial Performance, 2019-2021
Table 43 : Merck & Co. Inc.: Business Segment
Table 44 : Merck & Co. Inc.: Financial Performance, 2019-2021
Table 45 : Pfizer: Business Segment
Table 46 : Pfizer: Financial Performance, 2019-2021
Table 47 : Sanofi: Business Segments

Report Title: Monoclonal Antibodies for Oncology: Global Markets


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW